Literature DB >> 12628880

Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis.

Moira L Aitken1, Kelly E Greene, Mark R Tonelli, Jane L Burns, Julia C Emerson, Christopher H Goss, Ronald L Gibson.   

Abstract

STUDY
OBJECTIVES: Sputum induction (SI) is a noninvasive tool for sampling inflamed airways. The purpose of this study was to determine the optimal duration of collection in patients with cystic fibrosis (CF). The hypothesis was that the duration of SI collection would quantitatively and qualitatively alter the content of the induced sputum.
METHODS: In 10 clinically stable patients with CF (mean +/- SD age, 28 +/- 7 years; mean FEV(1), 2.6 +/- 0.7 L), SI was performed with 3% hypertonic saline solution at five time points over 20 min.
RESULTS: SI was well tolerated, with an average maximum fall in FEV(1) of 7 +/- 7%. The sample volumes, urea concentrations, interleukin-8 concentrations, total cell counts, and nonsquamous cell counts remained constant (p > 0.05). The percentage of neutrophils decreased from 89 +/- 5% to 86 +/- 4% (p = 0.03), and the percentage of alveolar macrophages increased 5 +/- 2% to 8 +/- 4% (p < 0.01). The mean quantitative microbiological counts of nonmucoid Pseudomonas aeruginosa and Staphylococcus aureus decreased over the 20-min time period each by half a log (p = 0.05 and p < 0.01, respectively). Surfactant protein-A concentration increased from 1.6 +/- 0.3 to 2.4 +/- 0.4 ng/mL (log(10); p < 0.001).
CONCLUSIONS: We conclude that aliquots of induced sputum are similar in clinically stable patients with CF during 4-min intervals, although there is more alveolar sampling after 20 min. When induced-sputum samples are fractionated for research monitoring of inflammatory or microbiologic indexes, power calculations accounting for these variations over time are required.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12628880     DOI: 10.1378/chest.123.3.792

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  15 in total

1.  The efficiency of sputum cell counts in cystic fibrosis.

Authors:  L Jayaram; N R Labiris; A Efthimiadis; H Valchos-Mayer; F E Hargreave; A P Freitag
Journal:  Can Respir J       Date:  2007-03       Impact factor: 2.409

2.  Safety of sputum induction with hypertonic saline solution in exercise-induced bronchoconstriction.

Authors:  Chris Carlsten; Moira L Aitken; Teal S Hallstrand
Journal:  Chest       Date:  2007-05       Impact factor: 9.410

Review 3.  Control of lung defence by mucins and macrophages: ancient defence mechanisms with modern functions.

Authors:  William J Janssen; Adrianne L Stefanski; Bruce S Bochner; Christopher M Evans
Journal:  Eur Respir J       Date:  2016-09-01       Impact factor: 16.671

4.  A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I.

Authors:  Li Ou; Michael J Przybilla; Ozan Ahlat; Sarah Kim; Paula Overn; Jeanine Jarnes; M Gerard O'Sullivan; Chester B Whitley
Journal:  Mol Ther       Date:  2020-04-08       Impact factor: 11.454

5.  Optimization of Recombinant Adeno-Associated Virus-Mediated Expression for Large Transgenes, Using a Synthetic Promoter and Tandem Array Enhancers.

Authors:  Ziying Yan; Xingshen Sun; Zehua Feng; Guiying Li; John T Fisher; Zoe A Stewart; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2015-04-20       Impact factor: 5.695

6.  Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling.

Authors:  Geraint B Rogers; Stuart Skelton; David J Serisier; Christopher J van der Gast; Kenneth D Bruce
Journal:  J Clin Microbiol       Date:  2009-11-11       Impact factor: 5.948

7.  Distinctive bronchial inflammation status in athletes: basophils, a new player.

Authors:  Beatriz Sastre; Mar Fernández-Nieto; María Jesús Rodríguez-Nieto; Erica Aguado; Joaquín Sastre; Victoria del Pozo
Journal:  Eur J Appl Physiol       Date:  2012-08-24       Impact factor: 3.078

Review 8.  Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis.

Authors:  Mark T Clunes; Richard C Boucher
Journal:  Curr Opin Pharmacol       Date:  2008-05-28       Impact factor: 5.547

Review 9.  Inhaled hypertonic saline for cystic fibrosis: Reviewing the potential evidence for modulation of neutrophil signalling and function.

Authors:  Emer P Reeves; Cormac McCarthy; Oliver J McElvaney; Maya Sakthi N Vijayan; Michelle M White; Danielle M Dunlea; Kerstin Pohl; Noreen Lacey; Noel G McElvaney
Journal:  World J Crit Care Med       Date:  2015-08-04

10.  Inhibitory effects of hypertonic saline on P. aeruginosa motility.

Authors:  Viktória Havasi; Casey O Hurst; Travis C Briles; Fan Yang; David G Bains; Daniel J Hassett; Eric Sorscher
Journal:  J Cyst Fibros       Date:  2008-01-31       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.